Abbott, GlaxoSmithKline expand agreement to develop companion diagnostic test

Nov. 29, 2011
Abbott Molecular (NYSE: ABT) and GlaxoSmithKline Biologicals S.A. (GSK) are expanding an existing agreement between the two companies to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program.

Abbott Molecular (NYSE: ABT; Abbott Park, IL) and GlaxoSmithKline Biologicals S.A. (GSK; Rixensart, Belgium) are expanding an existing agreement between the two companies to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program. Companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more or less likely to benefit from a particular therapy.

The existing agreements between the two companies, announced in July 2009 and March 2010, focused on the development of polymerase chain reaction (PCR) tests to screen non-small cell lung cancer and melanoma tumors for expression of the MAGE-A3 antigen. Under the expanded agreement, Abbott will develop a PCR test for use on its m2000rt instrument to screen non-small cell lung cancer tumors for the expression of the PRAME antigen. PRAME is a preferentially expressed antigen of melanoma that is expressed in 69 percent of non-small cell lung cancer cases, as well as in melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.

The expanded collaboration demonstrates Abbott's continued commitment to assessing biomarkers linked to immunotherapies in various cancers, says Stafford O'Kelly, head of Abbott's molecular diagnostics business. The agreement enables scientific advances in personalized medicine and companion diagnostics to help ensure that the right medicines get to the right cancer patients, he says.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow OptoIQ on your iPhone; download the free app here.

Subscribe now to BioOptics World magazine; it's free!

Sponsored Recommendations

Ask the Expert: Building Better Laser Micromachining Systems

Dec. 8, 2023
Dr. Cliff Jolliffe, Head of Strategic Marketing, Industrial Automation, Physik Instrumente (PI), fields questions about integrating controls for different motion systems and lasers...

Video: December 8, 2023 Photonics Hot List

Dec. 8, 2023
In this episode, we cover a microscopy method that hits uncharted cell territory, drone-based imaging for solar farm inspection, soliton microcombs that boost conversion efficiency...

China’s industrial laser market shows steady growth in turbulent times

Dec. 8, 2023
This in-depth market update focuses on trends in laser processing and industrial lasers while touching on what to expect in the ultrafast laser, fiber laser, LiDAR, and handheld...

What does it take to land venture capital for photonics-driven startups?

Dec. 7, 2023
Capital to grow a startup company can come from many sources: contract and non-recurring engineering (NRE) funding, angels and friends, customer upfront payments, and venture ...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!